This hypothesis is consistent with our in vitro findings: knockdown of Plexin-B1 reduces migration and invasion in prostate cancer cells expressing ErbB2, while activation of endogenous Plexin-B1 with Sema4D promotes migration and invasion. Here, ERBB2 is linked to prostate cancer.